This living guideline offers up-to-date guidance on the management of baseline immunosuppression (IS) for pre-existing rheumatic diseases (PRDs) when initiating cancer immunotherapy with immune checkpoint inhibitors (ICIs). Split into 2 parts, this guideline provides contemporary baseline IS recommendations for individuals with cancer and PRDs when initiating ICI therapy.
Part 1: includes recommendations for pre-existing inflammatory arthritides (rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, spondyloarthritis)
Part 2: includes recommendations for pre-existing systemic autoimmune rheumatic diseases (systemic sclerosis, systemic lupus erythematosus, Sjögen’s disease, myositis, vasculitis, Behcet’s disease, sarcoidosis)